Filter News

mRNA Therapeutics Market Size to Reach USD 37.89 BN by 2030

Published: Aug 04, 2022

According to Report Study, the global mRNA therapeutics market was valued at USD 33 billion in 2021 and it is predicted to surpass around USD 37.89 billion by 2030 with a CAGR of 1.55% from 2022 to 2030

Report Highlights

  • The infectious disease segment led the market and held 100% revenue share in 2021. 
  • The prophylactic vaccines segment dominated the market and captured 100% share in 2021. 
  • The hospitals and clinics segment captured the largest revenue share of over 60.0% in 2021 and is expected to register the fastest rate during the forecast period. 
  • North America dominated the market with over 35.06% share in 2021 and will emerge as the fastest-growing region during the forecast period. 
  • Europe captured the second-largest revenue share in 2021.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39429

One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs. The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.

Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favorable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.

For instance, in March 2022, The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.

As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.

The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39429

Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.

Scope of The Report

Report Coverage

Details

Market Size in 2021

USD 33 billion

Revenue Forecast by 2030

USD 37.89 billion

Growth rate from 2022 to 2030

CAGR of 1.55%
 

Base Year

2021

Forecast Period

2022 to 2030

Segmentation

Application, type, end-use, region
 

Companies Covered

Moderna, Inc.; BioNTech SE; CureVac N.V.; Arcturus Therapeutics; Translate Bio, Inc.; GSK plc.; Argos Therapeutics Inc.; Sangamo Therapeutics, Inc.; Pfizer Inc.; AstraZeneca plc.; CRISPR Therapeutics AG

 

Application Insights

The infectious disease segment led the market and held 100% revenue share in 2021. The increasing adoption of mRNA-based vaccines, a high number of candidates entering clinical trials for various infectious diseases, and the COVID-19 outbreak in late 2019 are anticipated to drive the market over the forecast period. The oncology segment is expected to expand at a lucrative rate over the forecast period. As per the World Health Organization (WHO) estimates, cancer accounted for approximately 10 million deaths in 2020, making it the leading cause of death globally.

Furthermore, lung, colon, rectum, liver, stomach, and breast cancers are some of the prevalent cancers that cause death. As a result, rising chronic illness incidence would ultimately increase the need for mRNA cancer vaccines and therapies, driving the market over the forecast period. Additionally, the lack of precision cancer therapy medications is pressuring the government and a number of important players to invest extensively in R&D. As a result, the demand for cancer vaccines and treatments is rising, thus driving the industry over the forecast period.

Type Insights

The prophylactic vaccines segment dominated the market and captured 100% share in 2021. According to the article in Nature's opinion, prophylactic vaccines are the focus of current R&D efforts, with 77% of mRNA businesses having at least one preventive vaccine in development. Additionally, COVID-19 products account for the vast majority of prophylactic vaccine revenues in the near term, while other vaccines for illnesses including influenza and respiratory syncytial virus also contribute to the segment growth.

Increased mergers and alliances and increased R&D efforts by pharmaceutical companies to improve various preventative vaccination kinds have a further impact on the market growth. For instance, in June 2022, Pfizer and Valneva announced the closing of equity investment for the development and commercialization of prophylactic vaccines for infectious diseases.

End-use Insights

The hospitals and clinics segment captured the largest revenue share of over 60.0% in 2021 and is expected to register the fastest rate during the forecast period. The widespread use of vaccines and therapeutics to treat a variety of chronic diseases is moving the market for personalized pharmaceuticals forward. The segment is also being driven by the increasing number of patients visiting hospitals and clinics.

Additionally, a rise in the number of patients with cancer, influenza, infectious diseases, and respiratory illnesses is expected to fuel the market growth. For instance, according to an NCBI report, in 2019, the WHO estimates that up to 500,000 people worldwide die from influenza each year and approximately one billion people are sick, thus contributing to the expansion of hospitals and healthcare clinics. 

Regional Insights

North America dominated the market with over 35.06% share in 2021 and will emerge as the fastest-growing region during the forecast period. The availability of significant research funding, expanding federal programs toward RNA-based medicines, and increasing number of clinical trials will drive the market in North America. For instance, in November 2020, The National Institutes of Health (NIH), the Defense Department, and federally funded academic laboratories have all supported Graham and others' basic research, which has been a crucial component in the quick development of vaccinations against COVID-19. Since the pandemic started, the government has invested an additional $10.5 billion in vaccine manufacturers to quicken the delivery of their products.

Europe captured the second-largest revenue share in 2021 owing to the increased patient population and awareness regarding rare genetic diseases. Moreover, there are major players operating in Europe, and there is an increasing need for mRNA vaccines and therapeutics in the region to create transformational treatments. For instance, as part of the U.S. biotech's expansion to "enable the delivery of mRNA vaccines and therapies locally," Moderna is expanding its wings across Europe (Denmark, Belgium, the Netherlands, Poland, Norway, and Sweden), which will increase the demand for mRNA vaccines and further drive the market over the forecast period.

Key Players

  • Moderna, Inc.
  • BioNTech SE
  • CureVac N.V.
  • Arcturus Therapeutics
  • Translate Bio, Inc.
  • GSK plc.
  • Argos Therapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Pfizer Inc.
  • AstraZeneca plc.
  • CRISPR Therapeutics AG 

Market Segmentation

  • By Application Outlook
    • Rare Genetic Diseases
    • Oncology
    • Respiratory Diseases
    • Infectious Diseases
    • Others
  • By Type Outlook
    • Prophylactic Vaccines
    • Therapeutic Vaccines
    • Therapeutic Drugs
  • By End-use Outlook
    • Hospitals & Clinics
    • Research Organizations
    • Others
  • By Regional Outlook
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39429

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

 

Back to news